Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | JDQ443 |
Trade Name | |
Synonyms | JDQ 443|JDQ-443|Opnurasib |
Drug Descriptions |
JDQ443 inhibits KRAS G12C, which may lead to inhibition of downstream signaling and tumor progression (PMID: 35404998). |
DrugClasses | KRAS G12C inhibitor 34 |
CAS Registry Number | NA |
NCIT ID | C177916 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Cetuximab + JDQ443 | Cetuximab JDQ443 | 0 | 1 |
IAG933 + JDQ443 | IAG933 JDQ443 | 0 | 0 |
JDQ443 | JDQ443 | 2 | 4 |
JDQ443 + Ribociclib | JDQ443 Ribociclib | 0 | 1 |
JDQ443 + Spartalizumab | JDQ443 Spartalizumab | 0 | 0 |
JDQ443 + Spartalizumab + TNO155 | JDQ443 Spartalizumab TNO155 | 0 | 0 |
JDQ443 + Tislelizumab | JDQ443 Tislelizumab | 0 | 1 |
JDQ443 + Tislelizumab + TNO155 | JDQ443 TNO155 Tislelizumab | 0 | 1 |
JDQ443 + TNO155 | JDQ443 TNO155 | 0 | 1 |
JDQ443 + Trametinib | JDQ443 Trametinib | 0 | 1 |